Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER3-DXd Monotherapy and Combinations in Advanced Breast Cancer (ICARUS-BREAST02)
NCT06298084Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in breast cancer (3 arms), sponsored by Gustave Roussy. Primary endpoints: Dose-Limiting Toxicities at 39 months, Frequency of safety events at 39 months and 9 more. Started Mar 2024; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06298084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298084.